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Aims: To assess potential causes of metformin intolerance, including altered metformin uptake
from the intestine, increased anaerobic glucose utilization and subsequent lactate production,
altered serotonin uptake, and altered bile acid pool.
Methods: For this pharmacokinetic study, we recruited 10 severely intolerant and 10 tolerant
individuals, matched for age, sex and body mass index. A single 500-mg dose of metformin was
administered, with blood sampling at 12 time points over 24 hours. Blood samples were ana-
lysed for metformin, lactate, serotonin and bile acid concentrations, and compared across the
phenotypes.
Results: The intolerant individuals were severely intolerant to 500 mg metformin. No signifi-
cant difference was identified between tolerant and intolerant cohorts in metformin pharmaco-
kinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7-2.3) mg/L and 2.0 (1.8-
2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area
under the curve (AUC)0–24 16.9 (13.9-18.6) and 13.9 (12.9-16.8) mg/L*h, respectively (P = .72).
Lactate concentration peaked at 3.5 hours, with mean peak concentration of 2.4 mmol/L in
both cohorts (95% CI 2.0-2.8 and 1.8-3.0 mmol/L, respectively), and similar incremental
AUC0–24 in each cohort: tolerant cohort 6.98 (95% CI 3.03-10.93) and intolerant cohort 4.47
(95% CI –3.12-12.06) mmol/L*h (P = .55). Neither serotonin nor bile acid concentrations were
significantly different.
Conclusions: Despite evidence of severe intolerance in our cohort, there was no significant dif-
ference in metformin pharmacokinetics or systemic measures of lactate, serotonin or bile acids.
This suggests that metformin intolerance may be attributable to local factors within the lumen
or enterocyte.
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1 | INTRODUCTION
Despite affecting up to 20% of those treated, metformin intolerance
is poorly understood.1 Intolerance to metformin is usually character-
ized by gastrointestinal (GI) side effects of nausea, abdominal pain,
bloating or diarrhoea. Gradual uptitration of dose after introduction
of metformin or slow release preparations can, in some cases, attenu-
ate symptoms of intolerance; however, in 5% of individuals exposed
to metformin, the severity of the GI side effect leads to discontinua-
tion of treatment.1 For others, metformin intolerance may result in
sub-optimal dosing or poor adherence. These factors delay optimal
glycaemic control in the individual, result in the addition of, or switch
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to, alternative oral anti-hyperglycaemic agents, and, as a result,
potentially contribute to increased risk of microvascular complications
of diabetes. Metformin is the first-line pharmaceutical treatment for
type 2 diabetes recommended by the American Diabetes Association
and European Association for the Study of Diabetes guidelines.2
These, and other guidelines,3 recommend metformin based on
prospective4–7 and retrospective8 studies that demonstrate an
improved glycaemic profile with metformin treatment, reduction in
cardiovascular mortality,4,6–8 no associated hypoglycaemia,5 and
weight neutrality or weight loss.5 These desirable characteristics,
along with their low cost, explain metformin’s status as the most
extensively prescribed anti-hyperglycaemic agent worldwide. These
same characteristics drive the need for ongoing research into the
mechanisms underlying intolerance to metformin, aiming to prevent,
modulate or treat intolerance. This would not only benefit the indi-
vidual but could have significant implications for health economy.
Metformin has a complex relationship with the gastrointestinal
tract.9 It is predominantly absorbed from the small intestine, with a
bioavailability of ~60%10; however, it also exerts many effects on the
intestine, as previously described.9 Multiple hypotheses for the mech-
anism of GI intolerance to metformin have been proposed, including
abnormal uptake, increased lactate production, and accumulation of
serotonin, histamine or bile acids.
Metformin uptake from the gut lumen is transporter-depen-
dent.10,11 Genetic variation12–15 in or inhibition12,14 of transporters,
such as organic cation transporter (OCT)1, could alter metformin
uptake from the intestinal lumen to enterocytes, and subsequently
affect efflux of metformin across the basolateral membrane to the
systemic circulation. This would lead to changes in metformin con-
centration within the GI tract, enterocytes or systemic circulation.
Previous studies have shown that metformin concentration in
enterocytes has been recorded at up to 300 times higher than the
systemic concentration,16 and the variation in transporter activity
described above could result in even greater differences in some indi-
viduals. Metformin is known to increase glucose uptake and anaero-
bic glucose utilization in the intestine, resulting in increased lactate
production.16–20 In humans, there is a small but significant increase in
systemic lactate when comparing those taking metformin with those
who are not.20 We suggest that metformin intolerance may be asso-
ciated with an increased concentration of metformin in the intestine,
or prolonged exposure of the enterocyte to metformin, leading to a
greater increase in anaerobic glucose utilization and lactate produc-
tion than in tolerant individuals. The increase in local lactate concen-
tration may contribute to the intolerance to metformin. Intracellular
lactate accumulation will lead to a subsequent increase in measurable
serum lactate.20
Metformin is known to stimulate the release of serotonin from
enterochromaffin cells,21 and is a substrate for serotonin transporter
(SERT).14,21,22 Metformin may inhibit the uptake of serotonin from
the intestinal lumen, leading to accumulation of serotonin in the gut.
Serotonin activates afferent neurons of the enteric nervous system,
and is responsible for peristaltic and secretory reflexes within the
intestine, as well as information transmission to the central nervous
system.23 Known serotonergic effects on the gut include nausea,
vomiting and diarrhoea,24 which are in-keeping with the GI side
effects seen in metformin intolerance. Histamine also increases gut
motility,25 and metformin may reduce the enterocytic metabolism of
histamine by diamine oxidase.22
It is recognized that metformin reduces ileal absorption of bile
acid,26 leading to an increase in the bile acid pool and potential
osmotic diarrhoea. Metformin could potentially alter the deconjuga-
tion of primary bile acids to secondary bile acids by bacterial 7α-
dehydroxylase27–29 as a result of the reduced diversity in the micro-
biome associated with metformin,30 specifically a reduction in the
genera known to produce 7α-dehydroxylase.
This open-label pharmacokinetic study investigated these
hypothesized mechanisms for metformin intolerance by studying how
individuals tolerant to metformin differed from those who are intoler-
ant. Plasma metformin and serum lactate concentrations were mea-
sured, along with targeted metabolomics, in the hours following the
administration of a single dose of immediate release metformin
500 mg.
2 | MATERIALS AND METHODS
This study was conducted in the Clinical Research Centre at Nine-
wells Hospital, Dundee, between June 2015 and April 2016. It was
co-sponsored by the University of Dundee and NHS Tayside, and
ethical approval was given by the East of Scotland Research Ethics
Committee. The study was conducted in accordance with the Good
Clinical Practice guidelines, and the Declaration of Helsinki. The study
was registered on the public database ClinicalTrials.gov (identifier
NCT03361878). Formal written informed consent was obtained from
each individual prior to inclusion.
2.1 | Recruitment and study design
Individuals were recruited if they had type 2 diabetes (T2D), were
white European, and met the criteria for tolerance or intolerance to
metformin. Metformin-intolerant individuals were defined as those
who had previously been treated with a maximum of 1000 mg met-
formin daily for a maximum of 8 weeks, and discontinued treatment
because of GI upset (Criterion 1). Alternatively, intolerance was
defined as inability to increase metformin dose above 500 mg with-
out experiencing GI side effects, despite having a glycated haemoglo-
bin (HbA1c) concentration >53 mmol/mol (Criterion 2). Tolerant
individuals were defined as those taking 2000 mg metformin daily in
divided doses, with no GI side effects. Those taking metformin were
asked to discontinue their metformin 72 hours prior to the study.
The length of washout period was based on an estimated t1/2 for
plasma metformin of 5.7 hours.10 Exclusion criteria were: inability to
consent; age not in the range of 18 to 90 years; estimated glomerular
filtration rate < 60 mL/min; pregnancy; history of gastric bypass; evi-
dence of slowed gastric or intestinal motility. None of the patients
included were treated with drugs known to affect the pharmacokinet-
ics of metformin in vivo,31 which are as follows: acarbose32; cephalex-
ine33; cimetidine34; dolutegravir35; pyramethamine36; ranolazine37;
trimethoprim38; and tyrosine kinase inhibitors.39
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A total of 10 metformin-intolerant individuals were recruited
from the DIRECT cohort40 in Tayside, 8 of whom met intolerance Cri-
terion 1. Ten metformin tolerant individuals were then recruited from
the GoDARTS41 cohort, after matching for gender, age and body
mass index (BMI).
Participants attended the Clinical Research Centre at Ninewells
Hospital and fasted from midnight. At 9:00 AM (time 0) a blood sam-
ple was obtained prior to administration of a single dose of immedi-
ate release oral metformin 500 mg. Further blood samples were
taken at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 and 24 hours post-metformin
administration. Urine was collected over the 24 hours post-
metformin administration. Participants were given breakfast 2 hours
and lunch 5 hours post-metformin administration. Plasma metformin
and lactate concentrations were measured at all time points, using
plasma lactate concentration as a proxy of intestinal lactate produc-
tion, secondary to metformin concentration within the enterocyte.
Plasma lactate was measured using a lactate oxidase method; plasma
and urine metformin concentrations were determined using liquid
chromatography and tandem mass spectrometry (LC-MS/MS), and
the limit of quantification was 0.01 mg/L. Histamine and serotonin
levels, and bile acids were determined using the targeted metabolo-
mic assays Biocrates AbsoluteIDQ p180 Kit and Biocrates Bile Acids
Kit, respectively. Full descriptions of analytical methods are provided
in the Supporting Information.
During the study, a Metformin Symptom Severity Score was com-
pleted by participants (Supporting Information in File S1). This ques-
tionnaire details the individual’s maximum tolerated dose of
metformin, identifies which GI side effects were experienced while
taking metformin, and scores the severity of the symptoms. This was
completed to confirm the phenotype of the cohorts, and gather infor-
mation as to the nature of the individuals’ side effects. The question-
naire was not used as a diagnostic tool in the present study, but as a
means of characterizing the intestinal intolerance experienced and the
perceived severity of this. The “true diagnosis” of intolerance was
based on the inclusion criteria alone.
2.2 | Statistical analysis
The primary endpoint was metformin pharmacokinetics as deter-
mined by the area under the curve (AUC) of metformin concentration
over time. The study was powered to detect a 30% difference in
AUC0–24 of the metformin concentration–time curve, with 80%
power, and significance of 5%. This value was chosen based on previ-
ous studies by Najib et al.,42 and required a cohort of 10 metformin-
intolerant individuals plus 10 metformin-tolerant individuals. The sec-
ondary objective of the study was to determine whether systemic
lactate concentration, a surrogate for metformin concentration in the
enterocyte, is associated with metformin intolerance. Additional
objectives included the assessment of serotonin, histamine and bile
acid concentrations in acute metformin dosing.
Pharmacokinetic data were analysed using non-compartmental
analysis using the R package NCAPPC,43 in conjunction with the
Department of Clinical Pharmacology and Pharmacy, Institute of Pub-
lic Health, University of Southern Denmark. Pharmacokinetic end-
points are presented as median with interquartile range (IQR; 25th to
75th percentiles) and geometric mean ratios with 95% confidence
intervals (CIs). Time to peak concentration (tmax) was determined
visually. AUC was estimated using the linear-up logarithmic-down
method. Statistical significance was determined using the unpaired
t test on log-transformed data and accepted at P < .05. Half-life was
estimated using the terminal slope (-ke) of the log-transformed plasma
metformin concentration–time curve, using the equation t1/2 = ln
(2)/ke.
Renal clearance of the drug from plasma (CLr) was estimated
using the following equation:
CLr = amount of substrate in urine0–24=AUCof substrate0–24
The apparent total clearance from plasma after oral administra-
tion (CL/F) was calculated using:
CL=F=dose=AUCof substrate
The bioavailability of metformin was not formally measured, as
this requires quantification of faecal recovery of metformin, and stool
samples were not obtained; however, estimated fractional drug avail-
ability (F) was calculated, by extrapolating our data to AUC0-inf. By
assuming that metformin is completely excreted by the kidneys, CL =
CLr, allowing the calculation of F by:
F = AUC0− inf=AUC0−24
 
× amount of metformin in urine0−24=doseð Þ
Creatinine clearance was calculated using the Cockcroft–Gault
equation using ideal body weight (IBW), and corrected for adjusted
body weight (ABW = IBW + 0.4 × [actual body weight – IBW]) in
those with BMI >25 kg/m2.
All other data were analysed using R studio, and were assessed
for normality using the Shapiro Wilks method. Those data with a nor-
mal distribution are expressed as mean  95% CIs and were com-
pared using unpaired t test with 2 tails and unequal variance. Graphic
data are plotted as mean  SEM. Those data with non-normal distri-
bution are expressed as medians with IQRs and compared using the
non-parametric Mann–Whitney U test.
Calculation of incremental AUC (iAUC) for lactate, serotonin and
bile acids used the linear trapezoidal method. For the purpose of the
present study and to minimize multiple testing penalties, we analysed
only serotonin and histamine from the Biocrates p180 panel, and
accepted values of P < .05 as statistically significant. For the analysis
of the bile acids panel, adjusting for the Bonferroni correction, we
accepted P < .0024.
3 | RESULTS
3.1 | Baseline characteristics and effect of acute
dosing
All 20 participants completed the study, with no withdrawals. The base-
line characteristics are listed in Table 1. The cohorts were well matched
for gender, age and BMI. There was no significant difference in creati-
nine clearance between the cohorts. HbA1c was different in the
2 cohorts: 60.4 (53.3-67.5) mmol/mol and 74.1 (69.0-79.2) mmol/mol
in the tolerant and intolerant cohorts, respectively, but this should not
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have affected the pharmacokinetics of metformin. This difference is not
surprising as the intolerant cohort had discontinued metformin, and
their higher HbA1c concentration may represent the difficulty in opti-
mizing their medical management. Both cohorts had additional anti-
hyperglycaemic medications prescribed, however, including sulphon-
lyureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors,
glucagon-like peptide-1 (GLP-1) receptor agonists and insulin. Addi-
tional medication was administered 2 hours post-metformin dosing.
The Metformin Symptom Severity Score was completed by all par-
ticipants, with a potential score ranging from 0 to 50. The intolerant
cohort had a mean severity score of 30.4, much greater than that of the
tolerant cohort (1.9; P < .0001). Of the 10 tolerant individuals, 8 scored
0 for the severity score, with the 2 individuals who scored 8 and 11 hav-
ing symptoms of irritable bowel syndrome which preceded metformin
and were unchanged by metformin treatment. Of the intolerant cohort,
70% of participants had previously experienced nausea with metformin,
50% described abdominal pain or bloating, and 50% had diarrhoea.
During the 24-hour study, 9 of the 10 intolerant individuals
experienced GI side effects after 500 mg of metformin, while none of
the tolerant cohort described any symptoms. Of the intolerant
cohort, 50% had diarrhoea, 50% experienced nausea, with 30%
describing abdominal pain, and 20% had bloating (Figure 1 and
Table S1 in File S2). However, as this is an open-label study, it is sus-
ceptible to reporting bias in those expecting symptoms of intolerance
with metformin, with a potential over-reporting of GI symptoms. It
should also be noted that the intolerance seen in the 24-hour study
period is acute intolerance. We cannot comment on chronic intoler-
ance, although our inclusion criteria identified individuals with true,
chronic intolerance.
3.2 | Metformin pharmacokinetics in intolerant and
tolerant individuals
At time 0 hours (pre-metformin dose) the intolerant group had a plasma
metformin concentration, as expected, under the limit of detection.
The metformin-tolerant group, despite 72 hours of metformin washout,
had a detectable metformin concentration, median (IQR) 0.067
(0.030-0.095) mg/L at baseline. Similarly, at 24 hours, the median (IQR)
metformin concentration in the tolerant cohort was higher (0.085
[0.066-0.135] mg/L) than the intolerant cohort (0.051 [0.034-0.066]
mg/L). Although the differences at baseline and at 24 hours post-
metformin are significantly different from zero (P < .001 and P = .015,
respectively), the levels are small when compared with the peak metfor-
min concentration after a 500-mg dose of metformin. Peak concentra-
tion (Cmax) for both cohorts was reached at 2.5 hours post-dose, with a
median (IQR) Cmax of 2.1 (1.7-2.3) mg/L and 2.0 (1.8-2.2) mg/L for the
tolerant and intolerant cohorts, respectively (P = .76). The plasma met-
formin concentrations of the groups, over 24 hours post 500 mg dose,
were not significantly different, with median AUC0–24 16.9 and
13.9 mg/L*h in the tolerant and intolerant cohorts, respectively
(P = .72), as shown in Figure 2. The t1/2 life of metformin was higher in
the tolerant group (4.8 vs 4.1 hours; P = .001); however, the apparent
oral volume of distribution, CL/F and CLr did not differ between the tol-
erant and intolerant groups (Table 2).
TABLE 1 Baseline characteristics
Characteristic
Metformin-
tolerant group
Metformin-
intolerant group P
Number of participants 10 10 1.000
Female/Male 7/3 7/3 1.000
Age, years 67.5 (60.8-72.5) 71.0 (65.75-80.3) .307
Age at diagnosis, years 51.5 (51.0-58.0) 60.0 (57.3-61.8) .111
Diabetes duration, years 12.0 (9.0-15.5) 12.0 (7.5-14.8) .850
HbA1c, mmol/mol 60.0 (55.0-68.0) 72.0 (67.3-76.8) .012
Weight, kg 90.0 (79.0-97.2) 91.2 (79.6-104.0) .910
BMI 34.6 (26.3-38.3) 34.3 (29.5-38.5) .800
Creatinine clearance 86.3 (76.6-107.3) 78.8 (68.3-93.2) .353
Sulphonylureas, n 3 6 .370
DPP-4 inhibitors, n 3 1 .582
GLP-1 receptor agonist, n 3 1 .582
Thiazolidinediones, n 0 2 .474
Insulin, n 4 4 1.000
Abbreviations: DPP-4, dipeptidyl peptidase; GLP-1 glucagon-like peptide-
1. Data are median (interquartile range), except where indicated other-
wise. P value for Mann–Whitney U test. For categorical data, P value for
Fisher’s exact test.
FIGURE 1 Symptoms of metformin
intolerance by phenotype, after a single
dose of metformin, 500 mg
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3.3 | Serum lactate and metformin intolerance
The lactate concentration increased post-metformin with the median
time to peak 3.5 hours post-dose (Figure 3). Mean peak lactate con-
centration was 2.4 mmol/L for both groups (tolerant 95% CI 2.0-2.8
and intolerant 95% CI 1.8-3.0). There was no significant difference in
the iAUC0–24 for lactate between the tolerant (6.98 mmol/L*h [95%
CI 3.03-10.93]) and intolerant (4.47 mmol/L*h [95% CI –3.12-12.06])
groups (P = 0.55).
3.4 | Plasma serotonin, histamine and bile acid
concentrations
The incremental AUC0–24 of the serotonin concentration–time curve
did not differ between the cohorts (P = .529), and there was no
apparent rise in plasma serotonin after metformin dosing in either
group (Figure S1 in File S2). Histamine levels were below the lower
limit of detection in the p180 panel for both cohorts.
The Biocrates bile acid panel measures the concentration of
20 different bile acids. There was no difference in incremental
AUC0–24 between the tolerant and intolerant cohorts for each indi-
vidual bile acid, when corrected for multiple testing. Similarly, when
considering the bile acids by class, primary, conjugated primary, sec-
ondary and conjugated secondary, no significant difference was iden-
tified (Table S2 in File S2).
4 | DISCUSSION
Metformin intolerance is a common and costly challenge in the man-
agement of type 2 diabetes. Despite metformin’s status as the first-
line medical treatment for type 2 diabetes, its mechanism of action is
still debated. Although it is widely accepted that metformin acts in
the liver to reduce gluconeogenesis,44 there is increasing evidence
that metformin may exert some of its effect via the gastrointestinal
tract,9 and it is unclear which of these potential mechanisms of action
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FIGURE 2 Plasma concentration of
metformin over time, after a single dose of
500 mg given at time 0 hours. Data points
are mean  SEM
TABLE 2 Pharmacokinetic characteristics after acute metformin dosing
Intolerant group
Median (IQR)
Tolerant group
Median (IQR) Geometric mean ratio (95% CIs)
P value
(unpaired t test)
AUC, mg/L*h 13.9 (12.9-16.8) 16.9 (13.9-18.6) 0.95
(0.72-1.26)
.72
Cmax, mg/L 2.0 (1.8-2.2) 2.1 (1.7-2.3) 1.04
(0.83-1.30)
.76
T1/2, h 4.1 (3.8-4.3) 4.8 (4.7-5.3) 0.82
(0.76-0.89)
<.001
CL/F, L/h 35.2 (29.4-38.1) 28.6 (25.8-34.6) 1.07
(0.81-1.43)
.62
V/F, L 211.4 (164.0-225.8) 197.3 (186.0-261.3) 0.88
(0.66-1.17)
.36
CLr, L/h 17.6 (13.9-25.5) 20.5 (14.7-25.2) 0.88
(0.56-1.41)
.59
F, % 71 (62-84) 95 (56-101) 0.83
(0.53-1.27)
.38
Abbreviations: CL/F, apparent total clearance from plasma after oral administration; CLr, renal clearance of the drug from plasma; F, estimated bioavail-
ability; V/F, volume of distribution.
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may be linked to metformin intolerance. In the present study of
extreme intolerance, we have shown for the first time that metformin
intolerance is unlikely to be mediated by differences in absorption,
distribution or elimination of metformin. We also showed that intol-
erance was not associated with lactate derived from anaerobic glu-
cose metabolism in the gut, altered systemic bile acid or serotonin
concentration.
Metformin uptake from the intestine is predominantly via 3 trans-
porters: OCT1; plasma membrane monoamine transporter (PMAT);
and SERT. In observational studies using GoDARTS data, Dujic
et al.12 demonstrated increased risk of metformin intolerance in those
with reduced function alleles for OCT1, and latterly SERT trans-
porters.14 Studies investigating the effect of OCT1 genotype on the
pharmacokinetics of metformin have reported varying results. Shu
et al.45 showed that, after acute dosing with metformin, the AUC of
metformin was significantly greater in those with OCT1 variants com-
pared with those with wild-type OCT1. However, steady-state phar-
macokinetics of metformin appear to be independent of OCT1
genotype.46 Christensen et al.15 identified a number of SNPs in
PMAT which were associated with reduced trough steady-state met-
formin concentrations, significant to the P < .05 level, but this result
did not withstand multiple testing. The above studies indicate that
systemic metformin concentration may differ according to transporter
genotype, and genotype has been associated with risk of intolerance;
therefore, we wanted to see if systemic metformin concentration
was associated with intolerance. The present study shows that,
despite a well defined extreme intolerant phenotype, with 90% of
the intolerant participants experiencing symptoms of metformin intol-
erance after a 500-mg dose, neither the Cmax nor tmax (and therefore
absorption) of metformin, were significantly different between
cohorts (Table 2). The lack of association of metformin pharmacoki-
netics with severe intolerance suggests that the association reported
of OCT1 and SERT variants altering metformin intolerance may
reflect an impact of these transporter variants on local rather than
systemic metformin concentrations.
We identified a surprising difference in baseline metformin con-
centration, resulting from detectable metformin in the plasma of the
tolerant group after 72 hours’ washout. The detection of metformin
after 72 hours washout may represent an improvement in metformin
assay: from gas chromatography, to high-performance liquid chroma-
tography and now liquid chromatography with tandem mass spec-
trometry. Results from the original pharmacokinetic studies of the
1970s would suggest 72 hours without metformin should result in
complete washout.47 The persistence of measurable plasma metfor-
min at 72 hours is likely to be indicative of a two- (or more) compart-
ment model, with metformin taken up and released slowly, for
example, by erythrocytes. The slow elimination phase of metformin
from the erythrocyte compartment has a t1/2 of 20 hours,
10,47,48
compared with a plasma t1/2 of 5.7 hours in subjects with normal
renal function.10 This is the likely cause of the difference in the calcu-
lated plasma t1/2 of the 2 cohorts, as the tolerant cohort had been at
steady-state while on metformin and probably had higher metformin
accumulation in secondary compartments. By contrast, the intolerant
group had depleted secondary compartments, which were absorbing
some of the excess metformin and leading to a shorter elimination
half-life.
Where transporter dysfunction may lead to reduced efflux and
the systemic concentration of metformin, it may also lead to
increased enterocytic or intraluminal metformin concentration.
Cycling of metformin between lumen and enterocyte, or uptake to
enterocyte with reduced efflux, could lead to increased local metfor-
min concentration. The resulting increase in glucose uptake and
anaerobic glucose utilization, leads to a subsequent rise in intracellu-
lar lactate concentration.16–20 As intracellular lactate rises, it is
released into the systemic circulation; therefore, measuring plasma
lactate concentration can be used as a proxy measure of lactate pro-
duction secondary to intestinal metformin concentration. Serum lac-
tate concentration was not significantly different between tolerant
and intolerant cohorts, indicating that enterocyte metformin concen-
tration was similar in both groups. Both groups did see a rise in
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lactate from 2 hours, peaking at ~3.5 hours post-dose, at a mean
maximum concentration of 2.4 mmol/L, which is above the normal
range in clinical practice. Portal venous sampling for lactate concen-
tration may provide a more accurate measure of intestinal lactate
production, when compared with peripheral concentrations, but this
is extremely challenging to carry out in humans and beyond the scope
of the present pharmacokinetic study.
The use of metabolomics to measure serotonin and bile acids
gave further insight into metformin intolerance. Serotonin was
detectable using the Biocrates p180 panel, but metformin dosing did
not increase serotonin concentrations; however, this does not
exclude a local effect of metformin on serotonin uptake by SERT. Bile
acid concentrations varied post-metformin dosing, but we did not
identify a difference in systemic concentrations of the individual or
grouped bile acid concentrations between tolerant and intolerant
cohorts. There was a trend toward a lower total AUC for deoxycholic
acid (DCA), a secondary bile acid from the conversion of cholic acid
by 7α-dehydroxylase, in the intolerant group (P = .052). This is inter-
esting as most bile acids are reabsorbed in the terminal ileum,
whereas DCA is absorbed from the colon.26 A reduced plasma con-
centration may indicate a reduced uptake of DCA, resulting in accu-
mulation in the colon, which could potentially lead to bile acid
diarrhoea. Further studies are required to investigate the role of the
microbiome, and subsequent changes to bile acid metabolism, in met-
formin intolerance.
We acknowledge that the present study has a number of limita-
tions. Firstly, the study had a small sample size, but was powered to
detect a 30% change in metformin AUC between cohorts. We
deemed a priori that this would be a clinically important difference
when comparing such extremes of intolerance. The similarity in the
mean concentrations for the 2 groups, and overlap of the distribu-
tions of individual values, are not consistent with these parameters
explaining the mechanism for the marked difference in tolerance seen
in these 2 groups. However, the point estimates for some of the
pharmacokinetic variables and lactate do differ and this difference
might achieve statistical significance if the sample size were much
larger so it is possible that more subtle differences in metformin phar-
macokinetics or the other measures evaluated do contribute to met-
formin intolerance. Secondly, we observed incomplete washout of
metformin in the tolerant cohort, which highlights the need for a lon-
ger washout in future studies, but as discussed above, the metformin
level at baseline was very low when compared to the peak post-dose
concentration and did not have an impact on the measures of metfor-
min absorption. Thirdly, metformin is known to increase GLP-1, and it
is possible that this may lead to gastrointestinal symptoms in some
cases; however, we were unable to measure GLP-1 in our study
cohort because of the concurrent use of DPP-4 inhibitors and GLP-1
receptor agonists. Finally, serum lactate concentration increased
2 hours post-metformin dosing, but a potential confounding factor
for this rise in lactate is the ingestion of a carbohydrate-rich meal at
2 hours post-metformin; however, previous studies in healthy volun-
teers indicate that the lactate concentrations increased transiently to
a maximum at 90 minutes post mixed meal, returning to baseline by
180 minutes.49 Participants in the study received a second
carbohydrate-rich meal at 5 hours post-metformin dosing, which did
not correspond to a further peak in serum lactate level. This supports
the conclusion that the rise in and peak lactate concentration is asso-
ciated primarily with metformin dosing, as opposed to ingestion of a
carbohydrate-rich meal.
In conclusion, in this pharmacokinetic study of well defined
extreme metformin-intolerant and metformin-tolerant individuals, we
ruled out multiple potential systemic effects of metformin that may
have contributed to metformin intolerance. We showed that the dif-
ferences between tolerant and intolerant cohorts in the absorption,
distribution or elimination of metformin, or in systemic lactate, sero-
tonin or bile acid concentrations, were too small to be the mechanism
of intolerance. It would be interesting to investigate further the link
between transporter genotype, pharmacokinetics and tolerance of
metformin, as genotype was not considered in the present study. To
do so, a large recruit-by-genotype study would be necessary. The
results from the present recruit-by-phenotype study suggest that
metformin intolerance is likely to be mediated by local factors
within the lumen or enterocyte. There is, therefore, a need to
undertake more mechanistic studies that investigate the local (lumi-
nal) environment, including the microbiome, in intolerant vs tolerant
individuals.
ACKNOWLEDGMENTS
We would like to thank research nurses Louise Cabrelli and Heather
Loftus for sample collection, and Clinical Research Centre laboratory
staff Gwen Kiddie and Louise King for sample processing. Thanks to
Dr James Burns for measurement of lactate concentrations per-
formed in the Department of Blood Sciences, Ninewells Hospital and
Medical School, Dundee. Thanks to Birgitte Damby Sørensen at the
Department of Public Health, Clinical Pharmacology and Pharmacy in
the University of Southern Denmark, for measurement of plasma and
urine metformin concentrations. We thank Julia Scarpa, Werner
Römisch-Margl and Silke Becker for metabolomics measurements
performed at the Helmholtz Zentrum München, Genome Analysis
Centre, Metabolomics Core Facility.
ORCID
Laura J. McCreight http://orcid.org/0000-0002-0880-4818
REFERENCES
1. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann
Intern Med. 2002;137:25-33.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hypergly-
cemia in Type 2 diabetes, 2015: a patient-centered approach: update
to a Position Statement of the American Diabetes Association and
the European Association for the Study of Diabetes. Diabetes Care.
2015;38:140-149.
3. National Institute for Health and Care Excellence. Type 2 Diabetes:
The Management of Type 2 Diabetes [NG28]. London: NICE; 2015.
4. Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood
glucose control with metformin on complications in overweight
patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):
854-865.
5. United Kingdom Prospective Diabetes Study Group. UK Prospective
Diabetes Study 24: relative efficacy of sulfonylurea, insulin and
MCCREIGHT ET AL. 7
metformin therapy in newly diagnosed non-insulin dependent diabe-
tes with primary diet failure followed for six years. Ann Intern Med.
1998;128:165-175.
6. Kao J, Tobis J, Mc Clelland RL. Relation of metformin treatment to
clinical events in diabetic patients undergoing percutaneous interven-
tion. Am J Cardiol. 2004;93:1347-1350. https://doi.org/10.1016/j.
amjcard.2004.02.028.
7. Kooy A, de Jager J, Lehert P. Long-term effects of metformin on
metabolism and microvascular and macrovascular disease in patients
with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616-625.
https://doi.org/10.1001/archinternmed.2009.20.
8. Johnson JA, Majumdar SR, Simpson SH. Decreased mortality associ-
ated with the use of metformin compared with sulfonylurea Mono-
therapy in type 2 diabetes. Diabetes Care. 2002;25:2244-2248.
https://doi.org/10.2337/diacare.25.12.2244.
9. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointesti-
nal tract. Diabetologia. 2016;59:426-435. https://doi.org/10.1007/
s00125-015-3844-9.
10. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of met-
formin. Clin Pharmacokinet. 2011;50:81-98. https://doi.org/10.2165/
11534750-000000000-00000.
11. Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR.
Four cation-selective transporters contribute to apical uptake and
accumulation of metformin in Caco-2 cell monolayers. J Pharmacol
Exp Ther. 2015;352:519-528. https://doi.org/10.1124/jpet.114.22
0350.
12. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER.
Association of organic cation transporter 1 with intolerance to met-
formin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64:
1786-1793. https://doi.org/10.2337/db14-1388.
13. Zhou K, Donnelly L, Yang J, et al. Heritability of variation in glycaemic
response to metformin: a genome-wide complex trait analysis. Lancet
Diabetes Endocrinol. 2014;2:481-487. https://doi.org/10.1016/S22
13-8587(14)70050-6.
14. Dujic T, Zhou K, Tavendale R, Palmer CNA, Pearson ER. Effect of
serotonin transporter 5HTTLPR polymorphism on gastrointestinal
intolerance to metformin: a GoDARTS study. Diabetes Care. 2016;
39(11):1896-1901. https://doi.org/10.2337/dc16-0706.
15. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmaco-
genetics of metformin and its impact on plasma metformin
steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet
Genomics. 2011;21(12):837-850. https://doi.org/10.1097/FPC.0b013
e32834c0010.
16. Bailey CJ, Wilcock C, Scarpello JHB. Metformin and the intestine.
Diabetologia. 2008;51:1552-1553. https://doi.org/10.1007/s00125-
008-1053-5.
17. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the
normal and diabetic mouse. Xenobiotica. 1994;24:49-57. https://doi.
org/10.3109/00498259409043220.
18. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabo-
lism in the splanchnic bed. Br J Pharmacol. 1992;105:1009-1013.
https://doi.org/10.1111/j.1476-5381.1992.tb09093.x.
19. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of
metformin-stimulated glucose utilization. Br J Pharmacol. 1994;112:
671-675. https://doi.org/10.1111/j.1476-5381.1994.tb13128.x.
20. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relation-
ship between metformin therapy and the fasting plasma lactate in
type 2 diabetes: the Fremantle Diabetes Study. Br J Clin Pharmacol.
2001;52:137-144. https://doi.org/10.1046/j.0306-5251.2001.01
423.x.
21. Cubeddu LX, Bönisch H, Göthert M, et al. Effects of metformin on
intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 recep-
tors. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:85-91. https://
doi.org/10.1007/s002109900152.
22. Yee SW, Lin L, Merski M, et al. Prediction and validation of enzyme
and transporter off-targets for metformin. J Pharmacokinet Pharmaco-
dyn. 2015;42:463-475. https://doi.org/10.1007/s10928-015-9436-y.
23. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal
motility and irritable bowel syndrome. Clin Chim Acta. 2009;403(1–2):
47-55. https://doi.org/10.1016/j.cca.2009.01.028.
24. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocri-
nol Diabetes Obes. 2009;16(1):53-59.
25. Deiteren A, De Man JG, Pelckmans PA, De Winter BY. Histamine H4
receptors in the gastrointestinal tract. Br J Pharmacol. 2015;172(5):
1165-1178. https://doi.org/10.1111/bph.12989.
26. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile
salt circulation and intestinal motility in type 2 diabetes mellitus. Dia-
bet Med. 1998;15:651-656. https://doi.org/10.1002/(SICI)1096-9136
(199808)15:8<651::AID-DIA628>3.0.CO;2-A.
27. Chiang JYL. Bile Acid Metabolism and Signaling. Compr Physiol. 2013;
3(3):1191-1212. https://doi.org/10.1002/cphy.c120023.
28. Takamine F, Imamura T. Isolation and characterization of bile acid
7-dehydroxylating bacteria from human feces. Microbiol Immunol. 1995;
39:11-18. https://doi.org/10.1111/j.1348-0421.1995.tb02162.x.
29. Begley M, Gahan CGM, Hill C. The interaction between bacteria and
bile. FEMS Microbiol Rev. 2005;29:625-651. https://doi.org/10.1016/
j.femsre.2004.09.003.
30. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in
European women with normal, impaired and diabetic glucose control.
Nature. 2013;498:99-103. https://doi.org/10.1038/nature12198.
31. Stage TB, Brøsen K, Christensen MMH. A comprehensive review of
drug–drug interactions with metformin. Clin Pharmacokinet. 2015;54:
811-824. https://doi.org/10.1007/s40262-015-0270-6.
32. Scheen A, de Magalhanes A, Salvatore T. Reduction of the acute bio-
availability of metformin by the α glycosidase inhibitor acarbose in
normal man. Eur J Clin Invest. 1994;24(suppl 3):50-54.
33. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan
Rao C, Madhusudan Rao Y. Effect of cephalexin on the pharmacoki-
netics of metformin in healthy human volunteers. Drug Metabol Drug
Interact. 2002;19(1):41-48.
34. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of met-
formin renal tubular secretion by cimetidine in man. Br J Clin Pharma-
col. 1987;23(5):545-551.
35. Zong J, Borland J, Jerva F, Wynne B, Choukour M, Song I. The effect
of dolutegravir on the pharmacokinetics of metformin in healthy sub-
jects. J Int AIDS Soc. 2014;17(4, suppl 3):19584.
36. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibi-
tor, pyrimethamine, on the renal elimination of metformin at oral
microdose and at therapeutic dose in healthy subjects. Clin Pharmacol
Ther. 2001;89:837-844. https://doi.org/10.1038/clpt.2011.36.
37. Zack J, Berg J, Juan A, et al. Pharmacokinetic drug–drug interaction
study of ranolazine and metformin in subjects with type 2 diabetes
mellitus. Clin Pharmacol Drug Dev. 2015;4:121-129.
38. Müller F, Pontones CA, Renner B, et al. N(1)-methylnicotinamide as
an endogenous probe for drug interactions by renal cation trans-
porters: studies on the metformin–trimethoprim interaction. Eur J Clin
Pharmacol. 2015;71:85-94.
39. Johansson S, Read J, Oliver S, et al. Pharmacokinetic evaluations of
the co-administrations of vandetanib and metformin, digoxin, midazo-
lam, omeprazole or ranitidine. Clin Pharmacokinet. 2014;53:837-847.
40. DIRECT - Innovative Medicines Initiative: DIabetes REsearCh on
patient straTification. http://www.direct-diabetes.org/project/.
Accessed October 30, 2017.
41. Hébert H, Shepherd B, Milburn K, et al. Cohort profile: Genetics of
Diabetes Audit and Research in Tayside Scotland (GoDARTS). Int J
Epidemiol. 2017. https://doi.org/10.1093/ije/dyx140 [Epub ahead of
print].
42. Najib N, Idkaidek N, Beshtawi M, et al. Bioequivalence evaluation of
two brands of metformin 500mg tablets (dialon &glucophage) in
healthy human volunteers. Biopharm Drug Dispos. 2002;23:301-306.
43. Acharya C, Hooker AC, Türkyýlmaz GY, Jönsson S, Karlsson MO. A
diagnostic tool for population models using non-compartmental anal-
ysis: the ncappc package for R. Comput Methods Programs Biomed.
2016;127:83-93.
44. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of
metformin: old or new insights? Diabetologia. 2013;56(9):1898-1906.
https://doi.org/10.1007/s00125-013-2991-0.
45. Shu Y, Brown C, Castro R, et al. Effect of genetic variation in the
organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Clin Pharmacol Ther. 2008;83(2):273-280. https://doi.org/10.1038/sj.
clpt.6100275.
8 MCCREIGHT ET AL.
46. Christensen MMH, Højlund K, Hother-Nielsen O, et al. Steady-state
pharmacokinetics of metformin is independent of the OCT1 genotype
in healthy volunteers. Eur J Clin Pharmacol. 2015;71:691. https://doi.
org/10.1007/s00228-015-1853-8.
47. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF.
Metformin kinetics in healthy subjects and in patients with diabetes
mellitus. Br J Clin Pharmacol. 1981;12:235-246.
48. Robert F, Fendri S, Hary L, Lacroix C, Andréjak M, Lalau JD. Kinetics
of plasma and erythrocyte metformin after acute administration in
healthy subjects. Diabetes Metab. 2003;29:279-283.
49. Woerle HJ, Meyer C, Dostou JM, et al. Pathways for glucose disposal
after meal ingestion in humans. Am J Physiol Endocrinol Metab. 2003;
284:E716-E725. https://doi.org/10.1152/ajpendo.00365.2002.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: McCreight LJ, Stage TB, Connelly P,
et al. Pharmacokinetics of metformin in patients with gastro-
intestinal intolerance. Diabetes Obes Metab. 2018;1–9.
https://doi.org/10.1111/dom.13264
MCCREIGHT ET AL. 9
